Receives R&D Tax Incentive of $2.6m
Receives R&D Tax Incentive of $2.6m
Sydney, Aug 29, 2017 AEST (ABN Newswire) - Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.6m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2017.

The Research and Development (R&D) tax incentive encourages companies to engage in R&D and innovation, benefiting Australia, by providing a tax offset for eligible R&D activities.

About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.



Sandra McIntosh
Company Secretary and Investor Relations
T: +61-2-9499-8010

Related Companies

Regeneus Ltd      

ABN Newswire This Page Viewed:  (Last 7 Days: 22) (Last 30 Days: 128) (Since Published: 2943) 

Regeneus Ltd NEWS: RECENT VISITS (7786)

Research Report

Social Media